Displaying 1–17 of 17 results for Patheon
Thermo Fisher officially acquired Patheon for $7.2 billion, entering the CDMO arena serving the pharmaceutical and biotechnology sectors
Patheon provides entry into the high-growth CDMO market and expands Thermo Fisher's biopharma services
Patheon Acquires Roche API Manufacturing Site. A major supply agreement with Roche accompanies the acquisition of the Florence, South Carolina, site.
The acquisition broadens the company's presence, product portfolio and customer network in Mexico
DPx Holdings B.V, the result of a $2.65 billion transaction between JLL Partners and Royal DSM finalized in March, has completed the transaction to acquire Gallus BioPharmaceuticals, LLC, a leading St. Louis-based contract manufacturing company specializing in biologics.
Winning projects for 2014 were selected from 27 well-qualified entries
$2.65 billion transaction combines the capabilities and expertise of Patheon and DSM Pharmaceutical Products to create industry powerhouse
DCAT Week '14, held March 10-14 in NYC, will address quality by design in a session titled, Quality by Design: Client, Contractor, and Regulatory Perspectives with Case Studies.
WellSpring appoints Lonnie Barish, MBA, as executive director of business development, and David Watt as technical director, pharma services
Royal DSM has confirmed that its biologics manufacturing operations and new Australian facility will be part of the business merged with Patheon in its agreement with JLL.
The new company anticipates 2014 sales of about $2 billion
Patheon acquires Banner Pharmacaps to build scale, expand capacity and broaden footprint in emerging markets
The global market for pharmaceutical contract manufacturing witnessed robust growth in recent years, and the future continues to hold tremendous prospects for the industry.
Contract drug developer Patheon said Wednesday it has let president and chief executive Wesley Wheeler go. Company chairman Ramsey Frank said Patheon has reached a stage where new leadership is required to realize its full potential. Peter Bigelow, president of Patheon's North American ...
Two five-year manufacturing agreements extend the partnership between the two companies.